Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study 

Videos

Dr. Lorenza Rimassa presents a five-year overall survival analysis from the Phase 3 HIMALAYA study, demonstrating sustained survival benefits of the STRIDE regimen versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC).

Five-year Overall Survival (OS) and OS by Tumor Response Measures from the Phase 3 HIMALAYA Study of Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (uHCC)

Lorenza Rimassa, MD, Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, Humanitas Research Hospital, discusses a study looking at tivantinib (ARQ 197), a highly selective MET inhibitor, for the treatment of Metastatic Colorectal Cancer (mCRC).

The study looked at tivantinib in Combination with cetuximab in EGFR inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) mCRC.

In the first stage of the study, three out of the 21 patients enrolled had an objective response and eight had stable disease. These results are exciting because all of the patients enrolled in the study had already become resistant to all of the treatment available, said Rimassa.

A phase II study with 41 patients has just completed enrollment. Results are expected at the end of the year.

Lorenza Rimassa, MD

Articles

Five-year Overall Survival (OS) and OS by Tumor Response Measures from the Phase 3 HIMALAYA Study of Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (uHCC)

Dr. Lorenza Rimassa on Tivantinib for EGFR Inhibitor-Resistant mCRC